Cytek Biosciences, Inc. CTKB Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$74M-11.2% | -$66.54M— | —— | —— | —— | ||
| $7.57M-0.1% | $7.58M+0.6% | $7.54M+0.9% | $7.47M+1.1% | $7.39M+2.4% | ||
| $22.82M-7.2% | $24.59M-5.7% | $26.06M-5.1% | $27.48M-1.3% | $27.84M+3.7% | ||
| $33.71M+0.5% | $33.56M+525% | -$7.91M-49.8% | -$5.28M-63.8% | -$3.22M-11.6% | ||
| -$369K+11.1% | -$415K-15.9% | -$358K-39.8% | -$256K-135% | -$109K-98.2% | ||
| $872K+111% | $413K— | —— | —— | —— | ||
| —— | —— | —— | $8.48M+164% | $3.21M-40.8% | ||
| —— | —— | $5.3M+1,196% | -$483K+94.3% | -$8.48M+42.5% | ||
| —— | —— | $2.02M-44.9% | $3.66M— | —— | ||
| $2.2M-44.6% | $3.97M— | —— | —— | —— | ||
| -$1.34M-151% | $2.66M+5,555% | $47K-98.8% | $3.77M+11,327% | $33K-98.8% | ||
| —— | —— | —— | —— | —— | ||
| $3.43M-4.7% | $3.6M+10.5% | $3.26M-31.2% | $4.74M+4.4% | $4.54M+21.4% | ||
| $4.34M-1.4% | $4.4M+6.3% | $4.14M+4.7% | $3.95M+12.1% | $3.53M+7.6% | ||
| —— | —— | —— | —— | —— | ||
| -$7.41M-54.5% | -$4.79M-137% | -$2.03M-113% | $15.09M-29.1% | $21.3M-16.1% | ||
| $5.4M+32.3% | $4.08M+2.7% | $3.98M-8.2% | $4.33M+13.8% | $3.81M+8.0% | ||
| $139K+28.7% | $108K+27.1% | $85K0.0% | $85K-46.5% | $159K-25.0% | ||
| $225K-10.7% | $252K+1.6% | $248K-7.5% | $268K-16.5% | $321K+11.5% | ||
| —— | —— | -$51.47M+40.3% | -$86.2M-23.5% | -$69.79M+17.9% | ||
| —— | —— | —— | $34.09M+5.7% | $32.25M+49.2% | ||
| $9.96M+78.4% | $5.58M-19.7% | $6.95M+42.9% | $4.87M+39.8% | $3.48M-16.8% | ||
| $4.1M-13.7% | $4.75M+144% | $1.94M+0.3% | $1.94M+0.2% | $1.94M+248% | ||
| $307K-5.5% | $325K-14.0% | $378K-2.6% | $388K-29.2% | $548K-46.0% | ||
| —— | —— | —— | -$29.87M-3.1% | -$28.98M-83.2% | ||
| $1.98M+1,719% | $109K-49.3% | $215K— | —— | —— | ||
| —— | —— | —— | -$102.45M-38.7% | -$73.84M-7.2% | ||
| -$1.59M-174% | $2.16M+11.8% | $1.93M-30.9% | $2.8M-27.0% | $3.83M0.0% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $3.43M-4.7% | $3.6M+10.5% | $3.26M-31.2% | $4.74M+4.4% | $4.54M+21.4% | ||
| -$1.16M-2.1% | -$1.13M+42.1% | -$1.96M-20.5% | -$1.62M-15.7% | -$1.4M-27.0% | ||
| —— | —— | —— | —— | —— | ||
| -$1.34M-151% | $2.66M+5,555% | $47K-98.8% | $3.77M+11,327% | $33K-98.8% | ||
| -$523K-59.5% | -$328K+95.5% | -$7.27M+1.0% | -$7.35M0.0% | -$7.35M-2.1% | ||
| $1.58M-7.1% | $1.7M+132% | $735K-22.1% | $944K-9.9% | $1.05M-36.3% | ||
| —— | —— | —— | -$5.93M-7.9% | -$5.5M-5.6% | ||
| $4.34M-1.4% | $4.4M+6.3% | $4.14M+4.7% | $3.95M+12.1% | $3.53M+7.6% | ||
| —— | —— | —— | —— | —— | ||
| $872K+111% | $413K— | —— | —— | —— | ||
| $139K+28.7% | $108K+27.1% | $85K0.0% | $85K-46.5% | $159K-25.0% | ||
| $225K-10.7% | $252K+1.6% | $248K-7.5% | $268K-16.5% | $321K+11.5% | ||
| $780K+16.4% | $670K+25.9% | $532K+4.9% | $507K-5.2% | $535K-3.4% | ||
| $4.1M-13.7% | $4.75M+144% | $1.94M+0.3% | $1.94M+0.2% | $1.94M+248% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $1K— | ||
| —— | —— | —— | $10.75M+224% | $3.32M+22.1% | ||
| -$1.59M-174% | $2.16M+11.8% | $1.93M-30.9% | $2.8M-27.0% | $3.83M0.0% | ||
| —— | —— | —— | —— | —— | ||
| -$12.7M-44.8% | -$8.77M-48.8% | -$5.9M-154% | $10.87M-37.9% | $17.49M-20.0% | ||
| -$12.7M-44.8% | -$8.77M-48.8% | -$5.9M-154% | $10.87M-37.9% | $17.49M-20.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cytek Biosciences, Inc. generate?
- Cytek Biosciences, Inc. (CTKB) generated -$7.4M in operating cash flow over the trailing twelve months.
- What is Cytek Biosciences, Inc.'s free cash flow?
- After $5.4M of capital expenditures, Cytek Biosciences, Inc.'s free cash flow was -$12.7M over the trailing twelve months, down 172.6% year over year.
- Where does Cytek Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
